Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer

Clinical Cancer Research

Volumn 6, Issue 7, 2000, Pages 2670-2676

  Breathnach, O S ^a,c   Georgiadis, M S ^a   Schuler, B S ^a   Pizzella, P ^b   Llorens, V ^a   Kasturi, V ^a   Steinberg, S M ^a   O'Neil, K ^b   Takimoto, C H ^a   Johnson, Bruce E ^a,c,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPERSENSITIVITY REACTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; SURVIVAL RATE;

EID: 0033941537     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Greenlee, R. T., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 2000. CA Cancer J. Clin., 50: 7-33, 2000.
2. Non-Small Cell Lung Cancer Cooperative Group. Chemotherapy in non-small cell lung cancer: meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br. Med. J., 311: 899-909, 1995.
3. Belani, C. P., Natale, R. B., Lee, J. S., Socinski, M., Robert, F., Waterhouse, D., Rowland, K., Ansari, R., Lilenbaum, R., and Sridhar, K. Randomized Phase III trial comparing cisplatin-etoposide versus carboplatin-paclitaxel in advanced and metastatic non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 17: 455, 1998.
4. Greco, F. A., and Hainsworth, J. D. Paclitaxel (1-hour infusion) plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter Phase II trial. Semin. Oncol., 24: S12-S17, 1997.
5. Rowinsky, E. K., Flood, W. A., Sartorius, S. E., Bowling, K. M., and Ettinger, D. S. Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. Investig. New Drugs, 15: 129-138, 1997.
6. Roychowdhury, D. F., Desai, P., and Zhu, Y. W. Paclitaxel (3-hour infusion) followed by carboplatin (24 hours after paclitaxel): a Phase II study in advanced non-small cell lung cancer. Semin. Oncol., 24: S12-S40, 1997.
7. Giaccone, G., Splinter, T. A., Debruyne, C., Kho, G. S., Lianes, P., van Zandwijk, N., Pennucci, M. C., Scagliotti, G., van Meerbeeck, J., and van Hoesel, Q. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. J. Clin. Oncol., 16: 2133-2141, 1998.
8. Langer, C. J., Leighton, J. C., Comis, R. L., O'Dwyer, P. J., McAleer, C. A., Bonjo, C. A., Engstrom, P. F., Litwin, S., and Ozols, R. F. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a Phase II toxicity, response, and survival analysis. J. Clin. Oncol., 13: 1860-1870, 1995.
9. Johnson, D. H., Paul, D. M., Hande, K. R., Shyr, Y., Blanke, C., Murphy, B., Lewis, M., and De Vore, R. F., III. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a Phase II trial. J. Clin. Oncol., 14: 2054-2060, 1996.
10. Bonomi, P., Kim, K., Fairclough, D., Cella, D., Kugler, J., Rowinsky, E., Jiroutek, M., and Johnson D. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J. Clin. Oncol., 18: 623-631, 2000.
11. Georgiadis, M. S., Russell, E. K., Gazdar, A. F., and Johnson, B. E. Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations. Clin. Cancer Res., 3: 449-454, 1997.
12. Lopes, N. M., Adams, E. G., Pitts, T. W., and Bhuyan, B. K. Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother. Pharmacol., 32: 235-242, 1993.
13. Liebmann, J. E., Cook, J. A., Lipschultz, C., Teague, D., Fisher, J., and Mitchell, J. B. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br. J. Cancer, 68: 1104-1109, 1993.
14. Rowinsky, E. K., Donehower, R. C., Jones, R. J., and Tucker, R. W. Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res., 48: 4093-4100, 1988.
15. Wilson, W. H., Berg, S. L., Bryant, G., Wittes, R. E., Bates, S., Fojo, A., Steinberg, S. M., Goldspiel, B. R., Herdt, J., and O'Shaughnessy, J. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a Phase I/II trial of a 96 hour infusion. J. Clin. Oncol., 12: 1621-1629, 1994.
16. Seidman, A. D., Hochhauser, D., Gollub, M., Edelman, B., Yao, T. J., Hudis, C. A., Francis, P., Fennelly, D., Gilewski, T. A., and Moynahan, M. E. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a Phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J. Clin. Oncol., 14: 1877-1884, 1996.
17. Markman, M., Rose, P. G., Jones, E., Horowitz, I. R., Kennedy, A., Webster, K., Belinson, J., Fusco, N., Fluellen, L., and Kulp, B. Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens. J. Clin. Oncol., 16: 1849-1851, 1998.
18. Socinski, M. A., Steagall, A., and Gillenwater, H. Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a Phase II trial. Cancer Invest., 17: 181-188, 1999.
19. Wilson, W. H., Chabner, B. A., Bryant, G., Bates, S., Fojo, A., Regis, J., Jaffe, E. S., Steinberg, S. M., Goldspiel, B. R., and Cheson, B. D. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J. Clin. Oncol., 13: 381-386, 1995.
20. Hudes, G. R., Nathan, F., Khater, C., Haas, N., Cornfield, M., Giantonio, B., Greenberg, R., Gomella, L., Litwin, S., and Ross, E. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J. Clin. Oncol., 15: 3156-3163, 1997.
21. Huang, K., Vaughn, D. J., Shaw, L. M., Recio, A., Bonner, H. S., and Haller, D. G. A Phase II trial and pharmacokinetic analysis of 96-hour infusional paclitaxel in patients with metastatic colorectal cancer. Am. J. Clin. Oncol., 21: 548-552, 1998.
22. Georgiadis, M., Schuler, B., Brown, J., Kieffer, L., Steinberg, S., Wilson, W., Takimoto, C., Kelley, M., and Johnson, B. E. Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a Phase I trial in patients with advanced lung cancer. J. Clin. Oncol., 15: 735-743, 1997.
23. Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. DCTD, NCI, NIH, DHHS, 1998.
24. Simon, R. Optimal two-stage designs for Phase II clinical trials. Control. Clin. Trials, 10: 1-10, 1989.
25. WHO. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: WHO, 1979.
26. Atkinson, E. N., and Brown, B. W. Confidence limits for probability of response in multistage Phase II clinical trials. Biometrics, 41: 741-744, 1985.
27. Kaplan, E., and Meier, P. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
28. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep., 50: 163-170, 1966.
29. Longo, D. L., Duffey, P. L., DeVita, V. T., Jr., Wesley, M. N., Hubbard, S. M., and Young, R. C. The calculation of actual or received dose intensity: a comparison of published methods. J. Clin. Oncol., 9: 2042-2051, 1991.
30. Mon, A., Bertoglio, S., Guglielmi, A., Aschele, C., Bolli, E., Tixi, L., Rosso, R., and Sobrero, A. Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil. Cancer Chemother. Pharmacol., 33: 179-180, 1993.
31. Younes, A., Ayoub, J. P., Hagemeister, F. B., McLaughlin, P., Sarris, A., Rodriguez, M. A., Swan, F., Jr., Romaguera, J. E., Martin, J., and Cabanillas, F. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule. J. Clin. Oncol., 14: 543-548, 1996.
32. Langer, C. J., Millenson, M., Rosvold, E., Litwin, S., McAleer, C. A., Bonjo, C. A., and Ozols, R. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a Phase II study of the Fox Chase Cancer Center and its network. Semin. Oncol., 24: S12-S88, 1997.
33. Akerley, W., Glantz, M., Choy, H., Rege, V., Sambandam, S., Joseph, P., Yee, L., Rodrigues, B., Wingate, P., and Leone, L. Phase I trial of weekly paclitaxel in advanced lung cancer. J. Clin. Oncol., 16: 153-158, 1998.
34. Akerly, W., Herndon, J., Egorin, M. J., Lyss, A., Kindler, H., Savarese, D., Sherman, C. A., Rosen, M. D., Ratain, M., and Green, M. R. CALGB 9731: Phase II trial of weekly paclitaxel for advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol., 18: 1783, 1999.
35. Schiff, P. B., Fant, J., and Horwitz, S. B. Promotion of microtubule assembly in vitro by Taxol. Nature (Lond.), 277: 665-667, 1979.
36. Ohtsu, T., Sasaki, Y., Tamura, T., Miyata, Y., Nakanomyo, H., Nishiwaki, Y., and Saijo, N. Clinical pharmacokinetics and pharmaco-dynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin. Cancer Res., 1: 599-606, 1995.
37. Rowinsky, E. K., Jiroutek, M., Bonomi, P., Johnson, D., and Baker, S. D. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Clin. Cancer Res., 5: 767-774, 1999.